Compare Stocks: BVS, LIVN, PLSE, and IRTC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BVS Bioventus	$13.30 -3.7%	$13.65	$6.47 ▼ $15.89	$1.16B	0.64	415,457 shs	332,985 shs
IRTC iRhythm Technologies	$108.66 -0.6%	$115.66	$100.70 ▼ $212.00	$3.60B	1.45	503,856 shs	398,635 shs
LIVN LivaNova	$77.58 -1.2%	$78.54	$48.82 ▼ $85.76	$4.32B	0.87	678,632 shs	773,981 shs
PLSE Pulse Biosciences	$44.43 -2.5%	$49.82	$12.56 ▼ $58.90	$3.23B	1.57	483,644 shs	327,406 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BVS Bioventus	+2.30%	+8.83%	+6.23%	+14.51%	+99.28%
IRTC iRhythm Technologies	+3.11%	+6.58%	-2.26%	-1.38%	-37.75%
LIVN LivaNova	+3.18%	+3.41%	-1.22%	-2.73%	+46.67%
PLSE Pulse Biosciences	-1.58%	-8.78%	-17.41%	+58.96%	+163.68%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BVS Bioventus	$13.30 -3.7%	$13.65	$6.47 ▼ $15.89	$1.16B	0.64	415,457 shs	332,985 shs
IRTC iRhythm Technologies	$108.66 -0.6%	$115.66	$100.70 ▼ $212.00	$3.60B	1.45	503,856 shs	398,635 shs
LIVN LivaNova	$77.58 -1.2%	$78.54	$48.82 ▼ $85.76	$4.32B	0.87	678,632 shs	773,981 shs
PLSE Pulse Biosciences	$44.43 -2.5%	$49.82	$12.56 ▼ $58.90	$3.23B	1.57	483,644 shs	327,406 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BVS Bioventus	+2.30%	+8.83%	+6.23%	+14.51%	+99.28%
IRTC iRhythm Technologies	+3.11%	+6.58%	-2.26%	-1.38%	-37.75%
LIVN LivaNova	+3.18%	+3.41%	-1.22%	-2.73%	+46.67%
PLSE Pulse Biosciences	-1.58%	-8.78%	-17.41%	+58.96%	+163.68%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BVS Bioventus	3.00	Buy	$16.80	26.32% Upside
IRTC iRhythm Technologies	2.94	Moderate Buy	$177.53	63.38% Upside
LIVN LivaNova	2.73	Moderate Buy	$87.75	13.11% Upside
PLSE Pulse Biosciences	2.86	Moderate Buy	$60.20	35.49% Upside

Current Analyst Ratings Breakdown

Latest BVS, LIVN, PLSE, and IRTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/16/2026	IRTC iRhythm Technologies	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$160.00
10/15/2026	PLSE Pulse Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/13/2026	PLSE Pulse Biosciences	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$55.00
10/13/2026	PLSE Pulse Biosciences	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$35.00 ➝ $60.00
10/12/2026	IRTC iRhythm Technologies	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/8/2026	BVS Bioventus	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C+) ➝ Buy (B-)
10/7/2026	LIVN LivaNova	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/6/2026	LIVN LivaNova	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Equal Weight ➝ Overweight	$105.00
10/6/2026	PLSE Pulse Biosciences	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$43.00 ➝ $58.00
10/6/2026	IRTC iRhythm Technologies	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$168.00 ➝ $150.00
10/5/2026	IRTC iRhythm Technologies	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$192.00 ➝ $194.00

(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BVS Bioventus	$568.09M	1.97	$1.23 per share	10.83	$2.76 per share	4.82
IRTC iRhythm Technologies	$747.14M	4.79	N/A	N/A	$4.74 per share	22.92
LIVN LivaNova	$1.39B	3.08	$4.78 per share	16.23	$21.98 per share	3.53
PLSE Pulse Biosciences	$350K	8,987.55	N/A	N/A	$1.19 per share	37.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BVS Bioventus	$22.73M	$0.77	18.17	14.94	1.76	9.36%	28.08%	9.82%	N/A
IRTC iRhythm Technologies	-$44.55M	-$0.43	237.72	76.52	N/A	-1.69%	10.11%	1.53%	10/29/2026 (Estimated)
LIVN LivaNova	-$242.47M	$3.38	21.87	18.65	N/A	12.82%	16.35%	7.76%	11/4/2026 (Estimated)
PLSE Pulse Biosciences	-$72.78M	-$1.18	N/A	N/A	N/A	-6,755.78%	-94.42%	-79.96%	11/4/2026 (Estimated)

Latest BVS, LIVN, PLSE, and IRTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	LIVN LivaNova	$1.06	N/A	N/A	N/A	$381.10 million	N/A
11/4/2026	Q3 2026	PLSE Pulse Biosciences	-$0.35	N/A	N/A	N/A	$0.52 million	N/A
10/29/2026	Q3 2026	IRTC iRhythm Technologies	$0.0230	N/A	N/A	N/A	$222.24 million	N/A
8/6/2026	Q2 2026	IRTC iRhythm Technologies	-$0.04	$0.58	+$0.62	-$0.01	$219.30 million	$224.17 million
8/6/2026	Q2 2026	LIVN LivaNova	$1.09	$1.26	+$0.17	$1.93	$380.50 million	$390.59 million
8/6/2026	Q2 2026	PLSE Pulse Biosciences	-$0.2933	-$0.36	-$0.0667	-$0.36	$0.53 million	$0.43 million
8/5/2026	Q2 2026	BVS Bioventus	$0.22	$0.22	N/A	$0.47	N/A	$153.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BVS Bioventus	N/A	N/A	N/A	N/A	N/A
IRTC iRhythm Technologies	N/A	N/A	N/A	N/A	N/A
LIVN LivaNova	N/A	N/A	N/A	N/A	N/A
PLSE Pulse Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BVS Bioventus	0.83	1.69	1.17
IRTC iRhythm Technologies	3.50	3.86	3.74
LIVN LivaNova	0.22	1.45	1.21
PLSE Pulse Biosciences	N/A	9.63	9.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BVS Bioventus	62.94%
IRTC iRhythm Technologies	N/A
LIVN LivaNova	97.64%
PLSE Pulse Biosciences	76.95%

Insider Ownership

Company	Insider Ownership
BVS Bioventus	33.50%
IRTC iRhythm Technologies	0.98%
LIVN LivaNova	0.35%
PLSE Pulse Biosciences	74.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BVS Bioventus	950	84.09 million	55.92 million	N/A
IRTC iRhythm Technologies	2,400	32.96 million	32.64 million	Optionable
LIVN LivaNova	3,300	55.09 million	54.90 million	Optionable
PLSE Pulse Biosciences	116	70.80 million	18.41 million	Optionable

BVS, LIVN, PLSE, and IRTC Headlines

Recent News About These Companies

Oppenheimer lifts target for Pulse Biosciences stock to USD 60.00

October 15 at 6:43 PM | ad-hoc-news.deA

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

October 14 at 9:14 AM | marketscreener.comM

Pulse Biosciences, Inc. Announces Commercial And Clinical Partnership With The Clayman Thyroid Center At The Hospital For Endocrine Surgery

October 14 at 9:14 AM | marketscreener.comM

Pulse Biosciences Partners With Clayman Thyroid Center To Expand Thyroid Nodule Treatment

October 14 at 9:14 AM | rttnews.com

Pulse Biosciences' 2027 Trial Readout Crucial to Evaluate New Pulsed Field Ablation Modality, Oppenheimer Says

October 13 at 6:46 PM | finance.yahoo.com

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 9, 2026

October 12, 2026 | biospace.comB

Head-To-Head Contrast: Pulse Biosciences (NASDAQ:PLSE) and NexGel (NASDAQ:NXGL)

October 11, 2026 | americanbankingnews.com

Why Pulse Biosciences (PLSE) Is Up 12.3% After Full NANOPULSE-AF Enrollment And nPulse Spotlight

October 10, 2026 | finance.yahoo.com

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 9, 2026 | businesswire.com

Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026

October 8, 2026 | finance.yahoo.com

Canaccord Genuity Sticks to Its Buy Rating for Pulse Biosciences (PLSE)

October 8, 2026 | theglobeandmail.com

Pulse Biosciences stock reaches 164 patient study target

October 8, 2026 | ad-hoc-news.deA

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment

October 7, 2026 | tmcnet.com

Pulse Biosciences Reaches Enrollment Target in Nanopulse-AF Study

October 7, 2026 | marketscreener.comM

Pulse Biosciences, Inc. Achieves Enrollment Target In NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse Cardiac Catheter System For Atrial Fibrillation Treatment

October 7, 2026 | marketscreener.comM

Pulse Biosciences, Inc (NASDAQ:PLSE) Stock Has Average Target Price of $50.20

October 6, 2026 | americanbankingnews.com

Pulse Biosciences, Inc (NASDAQ:PLSE) Stock Has Average Price Target of $50.20

October 6, 2026 | marketbeat.com

Pulse Biosciences (NASDAQ:PLSE) Shares Gap Down - Time to Sell?

October 5, 2026 | marketbeat.com

Pulse Biosciences stock faces Oppenheimer meeting after 3.87 percent fall

October 4, 2026 | ad-hoc-news.deA

Pulse Biosciences (PLSE) Stock Fair Value Rises After Analysts Back NsPFA Data

October 3, 2026 | finance.yahoo.com

Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 6.1% - Here's Why

September 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVS, LIVN, PLSE, and IRTC Company Descriptions

Bioventus NASDAQ:BVS

$13.30 -0.51 (-3.69%)

Closing price 04:00 PM Eastern

Extended Trading

$13.29 -0.01 (-0.08%)

As of 07:40 PM Eastern

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

iRhythm Technologies NASDAQ:IRTC

$108.66 -0.69 (-0.63%)

Closing price 04:00 PM Eastern

Extended Trading

$108.54 -0.13 (-0.12%)

As of 07:30 PM Eastern

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

LivaNova NASDAQ:LIVN

$77.58 -0.92 (-1.17%)

Closing price 04:00 PM Eastern

Extended Trading

$77.58 0.00 (0.00%)

As of 07:30 PM Eastern

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

Pulse Biosciences NASDAQ:PLSE

$44.43 -1.16 (-2.54%)

Closing price 04:00 PM Eastern

Extended Trading

$44.42 -0.02 (-0.03%)

As of 07:30 PM Eastern

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BVS, LIVN, PLSE, and IRTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BVS, LIVN, PLSE, and IRTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BVS, LIVN, PLSE, and IRTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVS, LIVN, PLSE, and IRTC Company Descriptions

Bioventus NASDAQ:BVS

iRhythm Technologies NASDAQ:IRTC

LivaNova NASDAQ:LIVN

Pulse Biosciences NASDAQ:PLSE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BVS, LIVN, PLSE, and IRTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BVS, LIVN, PLSE, and IRTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BVS, LIVN, PLSE, and IRTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVS, LIVN, PLSE, and IRTC Company Descriptions

Bioventus NASDAQ:BVS

iRhythm Technologies NASDAQ:IRTC

LivaNova NASDAQ:LIVN

Pulse Biosciences NASDAQ:PLSE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools